Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
Phase 1
- Conditions
- Lymphoma, B-Cell
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT02965157
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Tumor Hospital, Beijing, China
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
Phase 2
- Conditions
- Gastric Cancer
- Interventions
- Biological: autologous dendritic cells co-cultured with cytokine-induced killer cells
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT02504229
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Tumor Hospital, Beijing, Beijing, China
News
No news found